Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$229.69 USD

229.69
406,776

-1.01 (-0.44%)

Updated Aug 29, 2024 04:00 PM ET

After-Market: $229.74 +0.05 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (175 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

Investors are optimistic about Thermo Fisher (TMO) on strength in end markets and raised 2021 guidance.

Veeva Systems (VEEV) Digital Tools Boost Patient Engagement

Veeva Systems' (VEEV) enhancements in digital tools incorporate new ways for seamless communication among healthcare providers and field teams.

LH vs. COO: Which Stock Should Value Investors Buy Now?

LH vs. COO: Which Stock Is the Better Value Option?

Zimmer Biomet's (ZBH) Recovery Slows in Americas Amid Pandemic

The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).

CVS Health's (CVS) New Measures to Boost Omnichannel Health

CVS Health's (CVS) new measures will support its strategy of making health care more affordable, accessible and convenient for consumers.

LabCorp (LH) to Expand Nonclinical Development With New Buyout

LabCorp's (LH) acquisition of Toxikon can expand its full-service drug development and medical device solutions portfolio.

Phibro (PAHC) Sales Hurt by Staffing Shortage Amid Pandemic

Internationally, Phibro (PAHC) is registering growth in nutritional specialties driven by strong sales of dairy products.

Thermo Fisher (TMO) New Facility to Advance Lab Products Supply

Thermo Fisher's (TMO) new manufacturing facility will help the United States meet demand surges for vital laboratory products.

Bruker (BRKR) Advances in Proteomics Workflow With New Pacts

Talking about these three developments, Bruker (BRKR) notes that because of complex sample preparation protocols, the widespread adoption of proteomics has been limited.

Illumina (ILMN) iHope Genetic Health Program Expands WGS Access

Illumina's (ILMN) launch of iHope Genetic Health program will expand access to WGS to low- and middle-income communities worldwide.

Abbott (ABT) Introduces New Next-Generation Infant Formula

Abbott's (ABT) Similac 360 Total Care contains five different HMOs, similar to human breast milk, to support the health and development of an infant.

SmileDirectClub (SDC) Introduces Treatment Planning Software

SmileDirectClub's (SDC) SmileOS will enable its affiliated network of state-licensed doctors to treat more patients, better predict tooth movements and visualize patients' treatment.

Here's Why You Should Retain STERIS (STE) Stock For Now

Investors are optimistic about STERIS (STE) owing to its strong fiscal second-quarter results and bullish 2022 outlook.

Medtronic's (MDT) PillCam SB3 System Gets 510 (k) Clearance

Medtronic's (MDT) PillCam SB3 System provides a convenient option for a contactless procedure and helps ensure that patients can access care promptly.

Abbott (ABT) Aveir System Meets Primary Pivotal Trial Endpoints

Abbott's (ABT) Aveir pacing system has the potential to advance treatment for patients who need a pacemaker but where physicians are concerned about more invasive surgery.

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

Investors are optimistic about LabCorp (LH) backed by consistent recovery across its businesses and raised 2021 guidance.

Here's Why You Should Retain Edwards Lifesciences (EW) Stock

Investors are optimistic about Edwards Lifesciences (EW) on strong third-quarter results and bullish 2021 guidance.

Omnicell (OMCL) Inks New Deal to Manage Controlled Substances

Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

Robust performance across the Roto-Rooter segment and sequential growth in VITAS admissions are driving the top line for Chemed (CHE).

NuVasive (NUVA) Q3 Earnings Miss Estimates, 2021 Guidance Down

NuVasive (NUVA) reported lower-than-expected earnings and revenues with COVID-led headwinds and healthcare staffing shortages dampening the Q3 top-line growth.

Nevro (NVRO) Q3 Earnings Miss Estimates, Revenues Surpass

Nevro (NVRO) reported wider-than-expected loss during the third quarter with a year-over-year decline in revenues across U.S. and international businesses.

Integra (IART) Q3 Earnings Top Estimates, 2021 EPS View Up

Integra (IART) reports better-than-expected earnings and revenues with robust demand for the company's products driving the top line in third-quarter 2021.

Sanghamitra Saha headshot

5 Stocks Likely to Give Sweet Surprises on Earnings

These top-ranked stocks are likely to beat on the bottom line in their next releases.

Is LabCorp (LH) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

LH vs. COO: Which Stock Should Value Investors Buy Now?

LH vs. COO: Which Stock Is the Better Value Option?